NCT04451226 - A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

June 13, 2022

Study Completion Date

June 13, 2022

Conditions

Hot Flashes

Interventions

DRUG

Fezolinetant

Oral

Trial Locations (29)

Unknown

Site CN86002, Beijing

Site CN86015, Beijing

Site CN86029, Beijing

Site CN86032, Chengdu

Site CN86001, Guangzhou

Site CN86019, Guangzhou

Site CN86022, Guangzhou

Site CN86040, Guangzhou

Site CN86042, Guangzhou

Site CN86008, Hangzhou

Site CN86012, Hangzhou

Site CN86005, Hunan

Site CN86039, Jiangsu

Site CN86010, Jinlin

Site CN86020, Kunming

Site CN86037, Liuzhou

Site CN86006, Nanjing

Site CN86007, Nanjing

Site CN86018, Nanning

Site CN86034, Ningxia Hui Nationality Autonomous Region

Site CN86009, Shanghai

Site CN86011, Shanxi

Site CN86004, Shenzhen

Site CN86028, Shijiazhuang

Site CN86026, Suzhou

Site CN86038, Taiyuan

Site CN86030, Tianjin

Site CN86036, Tianjin

Site CN86025, Wuhan

All Listed Sponsors

lead

Astellas Pharma China, Inc.

INDUSTRY